NCT06589440View on ClinicalTrials.gov

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Interventions
DRUG

SR-8541A

SR-8541A administered orally in combination with intravenous botensilimab and balstilimab

Trial Locations (5)

75246

RECRUITING

Texas Oncology- Sammons- DFW, Dallas

75702

RECRUITING

Texas Oncology- Northeast Texas, Tyler

78745

RECRUITING

Texas Oncology- Austin, Austin

98104

RECRUITING

Swedish, Seattle

07960

RECRUITING

Atlantic Health, Morristown

Sponsors
All Listed Sponsors
lead

Stingray Therapeutics

INDUSTRY

NCT06589440 - Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) | Biotech Hunter | Biotech Hunter